New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
17:14 EDTAAPL, MSFT, AGN, SLXP, VRXOn The Fly: Closing Wrap
Stocks began the session in positive territory and remained there throughout the entire session. The move today marks the fourth higher close in the past five sessions and continues to keep August on track for the best monthly performance since February. The volume was light and the market drifted as there was little in the way of a catalyst since the market opened. Prior to the open however, the market received good news with housing starts and building permits data that was better than expected and the consumer prices report that was in-line with expectations. Investors will be a little more careful tomorrow as the Fed is scheduled to release its minutes from last month’s FOMC meeting. ECONOMIC EVENTS: Housing starts for July rose to an annualized pace of 1.093M units, up from 0.945M units in June, and beating expectations for 0.963M units... The Consumer Price Index increased 0.1% overall, matching expectations. Less food and energy, the CPI was up 0.1%, which was also in-line with the consensus forecast. COMPANY NEWS: Apple (AAPL) closed above $100 for the first time since the stock's seven-for-one split in June... Microsoft (MSFT) announced that former CEO Steve Ballmer has stepped down from the company's board, effective immediately. Microsoft shares traded up more than 1% today. MAJOR MOVERS: Allergan (AGN) approached Salix (SLXP) about a takeover, according to a Wall Street Journal report. Allergan is currently fighting a hostile takeover attempt by Valeant (VRX). Allergan traded up 4% today, Salix traded up 15.5%, and Valeant traded up 3.6%. INDEXES: The Dow was up 80.85, or 0.48%, to 16,919.59; the Nasdaq was up 19.20, or 0.43%, to 4,527.51; and the S&P 500 was up 9.86, or 0.5%, to 1,981.60.
News For AAPL;MSFT;AGN;SLXP;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | all recent news | >>
October 7, 2014
06:11 EDTAAPLApple adjusts supply ratio for iPhone 6 and iPhone 6 Plus, DigiTimes reports
Subscribe for More Information
06:09 EDTAAPLApple 12-inch tablet may integrate both Mac OS and iOS, DigiTimes reports
Subscribe for More Information
06:06 EDTAAPLApple reinstated with a Buy at BofA/Merrill
Subscribe for More Information
October 6, 2014
16:33 EDTSLXPProgenics receives $40M milestone payment from Salix
Subscribe for More Information
16:20 EDTAAPLOn The Fly: Closing Wrap
Stocks on Wall Street opened in positive territory and appeared ready to ride the wave of optimism from Friday’s jobs report into the new week. However, with little on the economic calendar to sustain the momentum, each of the major equity indexes had given up their gains by noon. The Dow and S&P 500 made it back to flat late in the session, but weakened into the close to end the day slightly lower. The tech-heavy Nasdaq was the laggard throughout and ended the day with the most significant decline. ECONOMIC EVENTS: In the U.S., no major economic data was reported. COMPANY NEWS: Hewlett-Packard (HPQ) climbed $1.67, or 4.74%, to $36.87 after it confirmed plans to split itself into two publicly traded companies by the end of its fiscal 2015. One company will include HP's technology infrastructure, software and services businesses, to be known as "Hewlett-Packard Enterprise," while the other will include the company's PC and printing businesses and be called "HP Inc." After the announcement, HP shares were upgraded to Outperform from Neutral at Credit Suisse, while analysts at Cantor called the split "a bold and smart move" that will give HP the financial flexibility needed to sell off one or both of the PC and printing businesses if an attractive offer emerges for either or both. MAJOR MOVERS: Among the notable gainers was Durata Therapeutics (DRTX), which surged $10.36, or 74.64%, to $24.24 after the company agreed to be acquired by larger drugmaker Actavis (ACT) for $23.00 per share in cash, or approximately $675M, and contingent value rights for additional cash payments of up to $5.00 per share if certain regulatory or commercial milestones related to Durata's lead product are achieved. Also higher was CareFusion (CFN), which jumped $10.58, or 22.92%, to $56.75 after agreeing to be acquired by Becton Dickinson (BDX) for $49 in cash and 0.0777 of a share of BD for each share of CareFusion, or about $12.2B. Becton Dickinson rose $9.14, or 7.89%, to $124.98 after its deal, while Actavis slipped $2.12, or 0.86%, to $243.95, after its own, much smaller purchase. GT Advanced Technologies (GTAT) plunged $10.22, or 92.46%, to 83c after the company announced that it and some of its units had commenced voluntary cases under chapter 11 of the bankruptcy code, which Raymond James believes implies a "fundamental, severe breakdown" of the company's relationship with Apple (AAPL). Also lower were shares of Sunesis (SNSS), which dropped $5.18, or 78.01%, to $1.46 and was downgraded at RBC Capital and Wells Fargo after a trial of a combination therapy for patients with first relapsed or refractory acute myeloid leukemia did not meet its primary endpoint. INDEXES: The Dow slid 17.78, or 0.1%, to 16,991.91, the Nasdaq fell 20.82, or 0.47%, to 4,454.80, and the S&P 500 slipped 3.08, or 0.16%, to 1,964.82.
16:00 EDTAAPLOptions Update; October 6, 2014
iPath S&P 500 VIX Short-Term Futures up 46c to 30.08. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX HPQ C RSH CLF PBR according to Track Data.
14:01 EDTAAPLGT Advanced bankruptcy implies breakdown with Apple, says Raymond James
Subscribe for More Information
11:41 EDTAAPLSolar companies sink after GT Advanced declares bankruptcy
Subscribe for More Information
11:15 EDTSLXP, AGNDurata surges after Actavis takeover
Shares of Durata Therapeutics (DRTX) are surging after the drugmaker agreed to be acquired by its larger industry peer, Actavis (ACT). WHAT'S NEW: Actavis announced it will commence a tender offer to acquire all of the outstanding shares of Durata common stock for $23.00 per share in cash, or approximately $675M in the aggregate, and contingent value rights entitling the holder to receive additional cash payments of up to $5.00 per share if certain regulatory or commercial milestones related to Durata's lead product Dalvance are achieved. If Dalvance is approved in Europe for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI, holders of the CVR will receive $1.00 per share. If Dalvance is approved for single dose administration by the FDA, holders of the CVR will receive $1.00 per share. If a net global Dalvance revenue threshold is met over a designated time period, holders of the CVR will receive $3.00 per share. Actavis expects the acquisition to be accretive by the end of the first year, it stated. WHAT'S NOTABLE: The acquisition comes after Durata Therapeutics was granted a Special Protocol Agreement by the FDA for its Phase 3 study of Dalvance on October 3. The study was designed to study Dalvance for the treatment of patients with community-acquired pneumonia and pediatric osteomyelitis. ANALYST REACTION: BMO Capital views the acquisition as a "good deal" for Actavis that is in line with CEO Brent Saunders' goal of making investments that complement its existing business. BMO believes the acquisition does not extend Actavis' balance sheet too far, and therefore does not prevent the company from doing additional deals. The firm expects there could be more deal-related news ahead for Actavis. The Fly notes Bloomberg reported on October 2 that Salix Pharmaceuticals (SLXP) was discussing selling itself to Actavis after failing to reach a deal with Allergan (AGN). PRICE ACTION: During morning trading, Durata Therapeutics gained $9.93, or 71.5%, to $23.81, Actavis slipped $1.95, or 0.8% to $244.12, and Salix fell $4.02, or 2.6%, to $148.85.
11:00 EDTSLXPOptions with decreasing implied volatilit
Subscribe for More Information
10:38 EDTAAPLApple's iPhone 6, 6 Plus to launch in India on October 17, Times of India says
Apple's iPhone 6 and iPhone 6 Plus will be available in India beginning Friday, October 17 through authorized resellers, the Times of India reports. Pre-orders for the devices start on October 7. The 16GB version o the iPhone 6 will be available at Rs 53,500, the 64GB version is priced at Rs 62,500 and the 128GB version of the phone will sell for Rs 71,500; the 16GB version of the iPhone 6 Plus will be available for Rs 62,500, while the 64GB version will cost Rs 71,500 and the 128GB version will sell for Rs 80,500. Reference Link
09:49 EDTSLXPActavis purchase of Durata leaves room for future deals, says BMO Capital
BMO Capital views Actavis' (ACT) deal to buy Durata Therapeutics (DRTX) as in line with its strategy of making investments that complement its existing business and as small enough that it does not prevent the company from doing additional deals. BMO expects there could be more deal-related news ahead for Actavis and keeps its Outperform rating on the stock. The Fly notes that that Bloomberg reported last week that Salix Pharmaceuticals (SLXP) was discussing selling itself to Actavis.
09:37 EDTAAPLActive equity options trading on open
Subscribe for More Information
08:07 EDTSLXP, AGNSalix slips in pre-market trade after Actavis strikes deal for Durata
Note that Bloomberg reported on October 2, citing people with knowledge of the matter, that Salix Pharmaceuticals (SLXP) was discussing selling itself to Actavis (ACT) after failing to reach a deal with Allergan (AGN). Actavis announced this morning that it has reached a deal to acquire Durata Therapeutics (DRTX) for $675M, or $23.00 per share. In pre-market trading, shares of Salix are down nearly 2% to $150 per share.
07:42 EDTAAPLSkyworks well positioned to benefit from iPhone upgrade cycle, says Canaccord
Subscribe for More Information
07:34 EDTAAPLApple updates software to protect against iWorm bug, MacRumors reports
Subscribe for More Information
07:16 EDTAAPLiOS 8 adoption appear slower than its predecessors, 9to5Mac reports
Subscribe for More Information
07:01 EDTAGNAllergan Q3 results likely to beat expectations, says Bernstein
Bernstein predicts that Allergan's Q3 EPS will exceed expectations by 15c, driven by cost cutting.
06:25 EDTAAPLiPhone 6 chip orders to remain high in 1Q15, DigiTimes reports
Subscribe for More Information
06:21 EDTMSFTMicrosoft 2015 solution may not help suppress Chromebook growth, DigiTimes says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use